Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Agios Pharmaceuticals is a clinical-stage biotechnology company focused on rare genetic metabolic diseases and genetically defined cancers. The company's lead commercial asset is PYRUKYND (mitapivat) for pyruvate kinase deficiency, generating modest revenue (~$100M TTM) while burning significant cash on R&D programs. With an 11.5x current ratio and minimal debt, Agios has runway to advance its pipeline, but the stock trades on binary clinical trial outcomes and regulatory milestones rather than current profitability.
Agios generates revenue primarily from PYRUKYND, an oral activator of pyruvate kinase for treating rare hemolytic anemias. The orphan drug designation provides market exclusivity and premium pricing (~$300K+ annual cost per patient estimated) in a small addressable population. The business model relies on expanding PYRUKYND's label (additional indications like thalassemia, sickle cell disease) and advancing early-stage pipeline assets targeting genetically defined metabolic disorders. Pricing power is strong in rare disease markets due to limited alternatives, but commercial success depends on payer coverage, physician adoption, and patient identification in ultra-rare populations (estimated 3,000-8,000 PK deficiency patients globally).
Phase 2/3 clinical trial data readouts for pipeline programs (thalassemia, sickle cell indications for mitapivat)
FDA regulatory decisions and label expansion approvals for PYRUKYND
Quarterly PYRUKYND prescription trends and revenue growth trajectory
Cash runway updates and financing announcements (equity raises, partnerships, asset sales)
Competitive developments in rare metabolic disease space and alternative therapies
Binary clinical trial risk - single failed Phase 3 study can eliminate 50-80% of market value overnight in small-cap biotech
Regulatory pathway uncertainty for rare disease indications with limited precedent and evolving FDA standards for accelerated approval
Reimbursement pressure from payers increasingly scrutinizing ultra-high-cost orphan drugs despite unmet need
Patent cliff risk - PYRUKYND composition of matter patents expire early 2030s, limiting commercial exclusivity window
Gene therapy competitors (CRISPR, bluebird bio) targeting same rare metabolic diseases with potentially curative one-time treatments versus chronic oral therapy
Larger pharma companies (Vertex, BioMarin) with superior commercial infrastructure entering rare disease markets through M&A or internal programs
Alternative treatment modalities (enzyme replacement, substrate reduction) advancing in overlapping patient populations
Cash burn of ~$400M annually against ~$500M cash (estimated) provides 12-15 month runway, requiring dilutive equity raise or strategic transaction by late 2026
Negative operating cash flow of -$400M TTM with no clear path to profitability without significant revenue inflection or cost cuts
Potential need to divest pipeline assets or out-license programs to extend runway if clinical data disappoints
low - Rare disease treatments are non-discretionary medical necessities with demand largely insulated from GDP fluctuations. Patient populations are small and clinically defined, not economically sensitive. However, severe recessions could pressure payer reimbursement rates or delay elective diagnostic testing that identifies patients.
Rising rates negatively impact valuation multiples for pre-profitable biotech (higher discount rates on distant cash flows) and increase opportunity cost versus fixed income. Financing costs rise if Agios needs to raise capital, though current minimal debt (0.03 D/E) limits direct interest expense impact. Rate increases typically compress biotech valuations 15-30% as risk-free alternatives become more attractive.
Minimal direct credit exposure. Strong balance sheet (11.5x current ratio, $500M+ cash estimated) provides self-funding capacity. However, tighter credit conditions reduce availability of venture debt or convertible financing if needed, and risk-off sentiment in credit markets correlates with biotech sector outflows.
growth - Speculative biotech investors seeking asymmetric returns from clinical catalysts and regulatory approvals. Attracts event-driven hedge funds around data readouts and venture-style investors willing to accept binary risk. Not suitable for value or income investors given negative earnings, no dividend, and high volatility. Recent -40% 3-month decline reflects risk-off rotation out of pre-revenue biotech.
high - Small-cap biotech with binary clinical catalysts exhibits 50-80% implied volatility. Stock can move 30-50% on single trial readouts. Beta likely 1.5-2.0x relative to broader market. Illiquidity (modest trading volume) amplifies price swings on sector rotation.
